CN115151305A - 用于治疗肾脏疾病的抗αvβ8整联蛋白抗体 - Google Patents

用于治疗肾脏疾病的抗αvβ8整联蛋白抗体 Download PDF

Info

Publication number
CN115151305A
CN115151305A CN202180010557.1A CN202180010557A CN115151305A CN 115151305 A CN115151305 A CN 115151305A CN 202180010557 A CN202180010557 A CN 202180010557A CN 115151305 A CN115151305 A CN 115151305A
Authority
CN
China
Prior art keywords
antibody
antigen
integrin
kidney
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180010557.1A
Other languages
English (en)
Chinese (zh)
Inventor
D·J·巴克
S·C·希斯曼
M·M·赫雷拉
梅林 E·利亚特
C·P·莫雷诺-奎恩
L·A·莫里
崔平
Y·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of CN115151305A publication Critical patent/CN115151305A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180010557.1A 2020-01-27 2021-01-26 用于治疗肾脏疾病的抗αvβ8整联蛋白抗体 Pending CN115151305A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062966258P 2020-01-27 2020-01-27
US62/966258 2020-01-27
PCT/EP2021/051753 WO2021151889A1 (en) 2020-01-27 2021-01-26 ANTI-αVβ8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE

Publications (1)

Publication Number Publication Date
CN115151305A true CN115151305A (zh) 2022-10-04

Family

ID=74561850

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180010557.1A Pending CN115151305A (zh) 2020-01-27 2021-01-26 用于治疗肾脏疾病的抗αvβ8整联蛋白抗体

Country Status (18)

Country Link
US (1) US20230112035A1 (https=)
EP (1) EP4096785A1 (https=)
JP (1) JP7706458B2 (https=)
KR (1) KR20220132567A (https=)
CN (1) CN115151305A (https=)
AR (1) AR121193A1 (https=)
AU (1) AU2021213403B2 (https=)
BR (1) BR112022014633A2 (https=)
CA (1) CA3167390A1 (https=)
CL (1) CL2022001999A1 (https=)
CO (1) CO2022011661A2 (https=)
CR (1) CR20220392A (https=)
EC (1) ECSP22066085A (https=)
IL (1) IL294814A (https=)
MX (1) MX2022009165A (https=)
PH (1) PH12022551863A1 (https=)
TW (1) TWI854088B (https=)
WO (1) WO2021151889A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117126282A (zh) * 2023-10-26 2023-11-28 迈威(上海)生物科技股份有限公司 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用
CN117143241A (zh) * 2023-10-26 2023-12-01 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11359024B2 (en) 2018-09-07 2022-06-14 Pfizer Inc. Anti-AVB8 antibodies and compositions and uses thereof
US20260035468A1 (en) 2022-09-12 2026-02-05 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
TW202446789A (zh) * 2023-03-31 2024-12-01 美商建南德克公司 抗αｖβ８整合素抗體及使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103490A2 (en) * 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
WO2013026004A2 (en) * 2011-08-17 2013-02-21 The Regents Of The University Of California Antibodies that bind integrin alpha-v beta-8
WO2015195835A2 (en) * 2014-06-17 2015-12-23 The Regents Of The University Of California Improved alpha-v beta-8 antibodies
WO2018227018A1 (en) * 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20170073406A1 (en) * 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CA3112523A1 (en) * 2018-08-08 2020-02-13 The General Hospital Corporation Integrin antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103490A2 (en) * 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
WO2013026004A2 (en) * 2011-08-17 2013-02-21 The Regents Of The University Of California Antibodies that bind integrin alpha-v beta-8
WO2015195835A2 (en) * 2014-06-17 2015-12-23 The Regents Of The University Of California Improved alpha-v beta-8 antibodies
WO2018227018A1 (en) * 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117126282A (zh) * 2023-10-26 2023-11-28 迈威(上海)生物科技股份有限公司 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用
CN117143241A (zh) * 2023-10-26 2023-12-01 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体
CN117126282B (zh) * 2023-10-26 2024-01-12 迈威(上海)生物科技股份有限公司 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Also Published As

Publication number Publication date
CR20220392A (es) 2022-09-07
JP7706458B2 (ja) 2025-07-11
CO2022011661A2 (es) 2022-08-30
TW202140554A (zh) 2021-11-01
JP2023511686A (ja) 2023-03-22
PH12022551863A1 (en) 2024-01-03
AU2021213403B2 (en) 2025-04-10
WO2021151889A1 (en) 2021-08-05
TWI854088B (zh) 2024-09-01
KR20220132567A (ko) 2022-09-30
ECSP22066085A (es) 2022-09-30
CA3167390A1 (en) 2021-08-05
MX2022009165A (es) 2022-08-16
EP4096785A1 (en) 2022-12-07
AU2021213403A1 (en) 2022-09-15
BR112022014633A2 (pt) 2022-09-13
AR121193A1 (es) 2022-04-27
IL294814A (en) 2022-09-01
CL2022001999A1 (es) 2023-01-27
US20230112035A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
TWI854088B (zh) 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體
RU2571224C2 (ru) Гуманизированные антитела против axl
CN112703013B (zh) Cd3抗原结合片段及其应用
CN104321342B (zh) Gremlin‑1抗体
EP2878670B1 (en) Antibody against transporter and use thereof
WO2021254481A1 (zh) 抗Claudin18.2抗体以及其用途
CN111741975B (zh) 抗血管生成素-2抗体及其用途
AU2020390028B2 (en) Pharmaceutical composition, preparation method therefor and use thereof
CN114761036A (zh) 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体
WO2015076425A1 (ja) 新規モノクローナル抗体
KR20210120008A (ko) Pd-l1 및 lag-3와 동시에 결합하는 신규 이중특이성 항체 분자 및 이중특이성 항체
CN113015751A (zh) 一种融合蛋白及其用途
TW201946658A (zh) 抗ｇｉｔｒ抗體及其用途
WO2019238074A1 (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
CN118852427A (zh) 靶向cd70的单克隆抗体及其用途
KR20230142768A (ko) Ccdc112를 기반으로 하는 종양세포 성장을 억제하는 방법 및 적용
KR20230135627A (ko) 항-PDGF-b 항체 및 폐동맥 고혈압 (PAH)을 치료하기 위한 사용 방법
EA049172B1 (ru) АНТИТЕЛА К ИНТЕГРИНУ αvβ8 ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ПОЧЕК
WO2024260384A1 (en) Antibodies or antigen-binding fragments binding to lilrb1 and uses thereof
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination